Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
Rukhmani Keshwani v. Raju Agarbatti Works & Anr. , FAO (COMM) 99/2024 (Delhi High Court, Division Bench, decided 01.07.2026) Why This Case Matters For any business that sells through a website, a marketplace listing, or a platform like IndiaMart, Amazon, or Etsy, this ruling answers a question that keeps coming up in Indian IP litigation: can you be sued for trademark or copyright infringement in a city where you have no office, no warehouse, and no employee — simply because your goods are listed online and reachable there? The Delhi High Court's answer, reaffirming and extending its own recent line of authority, is yes — provided the online listing shows purposeful commercial targeting , not mere passive accessibility. Actual completed sales are not required. This has direct consequences for how foreign and domestic manufacturers, franchisors, and e-commerce sellers should think about litigation risk exposure across Indian jurisdictions. The Dispute in Brief R...